News

Toys”R”Us unwraps annual holiday hot toy list

BY DSN STAFF

WAYNE, N.J. — Toys“R”Us announced this week its top toy list for the holiday season.

This year’s list, which features new items for kids of all ages, includes:

  • Air Hogs Hyper Actives from Spin Master;

  • Air Swimmers eXtreme from Animal Planet;

  • Lalaloopsy Silly Hair dolls from MGA Entertainment;

  • LeapPad Explorer from LeapFrog;

  • Monster High Fearleading 3-Pack from Mattel;

  • Moshi Monsters Moshling 3-Pack Mini-Figures from Spin Master;

  • My Keepon from Wow! Stuff;

  • Nerf Vortex Vigilon from Hasbro;

  • Ninjago Lightning Dragon Battle from Lego;

  • Poppin’ Park Elefun Busy Ball Popper from Playskool;

  • Power Wheels Dune Racer from Fisher-Price;

  • Radica Fijit Friends from Mattel;

  • Sesame Street Let’s Rock! Elmo from Hasbro;

  • Skylanders: Spyro’s Adventure from Activision; and

  • The Trash Pack Garbage Truck from Moose Toys.

"There are so many really terrific new toys available this year, so narrowing down the list of top toys was fun, but challenging," Toys"R"Us SVP and chief merchandising officer Karen Dodge said. "The Toys"R"Us 2011 holiday hot toy list highlights what we expect will be the most sought-after items this holiday season and the ones that will yield squeals of delight when kids tear off the wrapping paper on Christmas morning."

In related news, Kmart also unveiled its top toy list this week. 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

News

Walgreens celebrates 80th anniversary of Marquette University store

BY Allison Cerra

DEERFIELD, Ill. — Walgreens on Thursday marked the 80th anniversary of a Milwaukee-based store that continues to serve the students and surrounding community of Marquette University.

The store, located on 16th St. and Wisconsin Ave., is the second-oldest Walgreens that still operates at its original location, the drug store chain said. The store experienced several innovations rolled out by Walgreens, including "touch-tone prefills," large-type prescription instructions and offering immunizations daily with no appointment necessary.

“Outside of one other Walgreens in Tennessee, no other store in the chain has ever celebrated this milestone,” Walgreens district manager Rob Wucki said. “For eight decades, we’ve been the go-to destination for the health and daily living needs of Marquette students and the community at large. We’re proud to call 16th and Wisconsin home and committed to many more years of service to come.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

News

BMS, Ambrx ink deal to research, develop, commercialize diabetes, heart failure biologics

BY Allison Cerra

PRINCETON, N.J., and LA JOLLA, Calif. — Two drug makers have entered a collaboration for novel biologics programs in diabetes and heart failure.

Under the partnership, Bristol-Myers Squibb will receive exclusive worldwide rights to research, develop and commercialize biologics, based on research by Ambrx of fibroblast growth factor 21 (FGF-21) protein and relaxin hormone, which potentially can treat Type 2 diabetes and heart failure, respectively.

Under the terms of the agreement, Bristol will make an upfront payment of $24 million to Ambrx, as well as potential milestone payments and royalty payments on worldwide sales for both programs. Bristol and Ambrx also will enter research collaborations for both programs.

The lead compound in the FGF-21 program, ARX618 (or PEG-FGF-21) is in the final stages of preclinical development, while the relaxin program is in preclinical development.

“Bristol-Myers Squibb has a strong heritage discovering, developing and delivering medicines to treat diabetes and cardiovascular disease,” Bristol-Myers Squibb SVP Francis Cuss said. “We are excited to be working with Ambrx, which has used its unique ReCode technology to create precisely engineered investigational biologics in both of these therapeutic areas. Our combined expertise will provide the best chance of bringing these innovative medicines to patients.”

“These programs have shown tremendous potential in preclinical studies, and we believe that Bristol-Myers Squibb has the necessary expertise to best lead their continued development,” Ambrx chief business officer Simon Allen said. “We look forward to using the revenues from this partnership to continue to grow our internal pipeline, which includes our promising antibody drug conjugate programs.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES